Molecular characterization of chikungunya viruses associated with outbreaks in Kenya from 2017 to 2020

This study characterizes the molecular epidemiology of Chikungunya virus outbreaks in Kenya from 2017 to 2020, revealing that Indian Ocean Lineage strains with fitness-enhancing mutations caused geographically distinct but related transmission clusters in Mombasa and Dadaab-Hagadera, while identifying specific clinical symptoms that can aid in differentiating Chikungunya from other acute febrile illnesses in resource-limited settings.

The Gist

Imagine Kenya as a bustling neighborhood where a sneaky, invisible troublemaker called the Chikungunya virus (let's call him "Chik") keeps popping up to throw parties that no one wants to attend. These parties cause high fevers and terrible joint pain.

For a long time, people in Kenya knew Chik was around, but they didn't have a clear picture of who he was, where he was hiding, or how he was changing his disguise between 2017 and 2020. This paper is like a detective story where scientists put on their magnifying glasses to solve three main mysteries.

1. The Genetic Fingerprint: "Who is Chik?"

Scientists took samples from two different trouble spots: Mombasa (a busy coastal city) and Dadaab-Hagadera (a large refugee camp near the border). They sequenced the virus's DNA, which is like reading the virus's ID card.

• The Big Reveal: They found that Chik wasn't a new stranger; he was part of a specific family known as the Indian Ocean Lineage. Think of this family as a specific gang of criminals that has been causing trouble in the region for years.
• The Two Clans: Even though they were the same family, the "Mombasa gang" and the "Dadaab gang" had slightly different tattoos.
  • The Mombasa viruses were like a tight-knit group of friends who had been hanging out locally for a while, sharing specific genetic "tattoos" (mutations) that made them very good at infecting mosquitoes.
  • The Dadaab viruses were a separate, smaller group with their own unique style, though they shared a few key "tattoos" with the Mombasa group.
• The Superpower: Both groups had a special superpower mutation (a tiny change in their code called E1-A226V). Imagine this mutation as a universal key that unlocks the door to a specific type of mosquito (Aedes aegypti). Because they have this key, they can spread much faster and more easily than older versions of the virus.

2. The Disguise: "How did he change?"

Viruses are like shape-shifters. When the scientists grew the virus in a lab (like putting it in a test tube gym), they noticed it started changing its shape to get stronger.

• The Gym Effect: Just like a bodybuilder gains muscle after working out, the virus gained "muscle" (mutations) when it was passed through cells in the lab. It changed its outer shell to stick better to cells.
• The Warning: The scientists noticed that the virus is constantly tweaking its armor. Some of these tweaks (mutations) might make the virus even better at spreading or surviving in new environments. It's like the virus is constantly upgrading its software to avoid being caught.

3. The Symptoms: "How do we spot him in a crowd?"

This is the most practical part of the story. In a crowded hospital, many people come in with fevers. Some have malaria, some have dengue, and some have Chikungunya. It's hard to tell them apart because they all look sick.

The scientists acted like detectives looking for clues to separate Chik from the other "fever suspects." They compared the symptoms of people who definitely had Chik against people who had other fevers.

• The "Chik" Clues: If a patient has a fever AND is complaining of:
  • Sore muscles (like they ran a marathon),
  • Headaches, or
  • Convulsions (seizures),
    ...there is a much higher chance it's Chik.
• The "Not Chik" Clue: If the patient has diarrhea (loose stools), it's actually less likely to be Chik. Think of diarrhea as a "red flag" that points to a different culprit.
• The Red Herrings: Things like coughing, skin rashes, or vomiting didn't help much. They were just as likely to happen with other diseases, so they weren't good clues for spotting Chik.

Why Does This Matter?

Imagine you are a doctor in a small clinic without fancy machines to test for every virus. You need to know who to treat and how to warn the community.

• Better Diagnosis: By knowing that "sore muscles + no diarrhea" is a strong sign of Chik, doctors can suspect it earlier and tell patients to stay home to avoid spreading it to mosquitoes.
• Future Proofing: Since the virus is constantly changing its "tattoos" (mutations), we need to keep watching it. If it gets a new superpower, our current vaccines or control methods might need an update.

In a nutshell: This paper tells us that Chikungunya is still active in Kenya, it has a specific "gang" identity that is very good at using local mosquitoes, and we can spot it better by looking for muscle pain and headaches while ignoring diarrhea. It's a warning to stay alert, because this virus is smart, adaptable, and always looking for its next party.

Technical Summary

1. Problem Statement

Chikungunya virus (CHIKV) is a re-emerging vector-borne alphavirus causing significant morbidity, including acute fever and polyarthritis. In Kenya, CHIKV is endemic to the coastal region, with major outbreaks recorded in 2004 (Lamu/Mombasa), 2014 (Kilifi), and 2016 (Mandera). However, information regarding subsequent outbreaks between 2017 and 2020 was scarce.

• Diagnostic Challenge: CHIKV symptoms overlap significantly with other Acute Febrile Illnesses (AFIs) such as malaria and dengue, leading to potential misdiagnosis and underreporting, especially in regions with limited laboratory capacity.
• Knowledge Gap: There was a lack of molecular data characterizing the specific viral lineages circulating in Kenya during the 2017–2020 period, their evolutionary relationship to previous outbreaks, and the presence of mutations associated with increased vector fitness (e.g., in Aedes aegypti and Aedes albopictus).
• Clinical Gap: There was a need to identify specific clinical predictors that could differentiate CHIKV from other AFIs in the Kenyan context to improve triage and diagnosis.

2. Methodology

The study employed a retrospective design combining molecular epidemiology and clinical data analysis.

• Sample Collection:
  • Source: 42 CHIKV-positive samples archived at the Kenya Medical Research Institute (KEMRI) between December 2017 and February 2020.
  • Locations:
    • Mombasa: 32 samples from an AFI surveillance study at Coast General Hospital (whole blood/serum).
    • Dadaab-Hagadera: 9 samples from a 2020 outbreak investigation in a refugee camp near the Somalia border.
  • Viral Isolation: One sample from Dadaab-Hagadera was successfully passaged three times in Vero cells to generate a viral isolate (S32) for sequencing.
• Laboratory Procedures:
  • Detection: Samples were tested via TaqMan Array Card (TAC) for Mombasa and specific RT-PCR for Dadaab-Hagadera.
  • Sequencing: Whole-genome sequencing was performed using Illumina MiSeq technology. Primers were designed to cover >99% of the CHIKV genome.
  • Bioinformatics: Reads were aligned using Bowtie2, variants detected with LoFreq, and de novo assembly performed with SPAdes.
• Phylogenetic Analysis:
  • Bayesian phylogenetic trees were constructed using BEAST v1.8.4 with a TN92+G substitution model and an uncorrelated relaxed clock.
  • Sequences were compared against four reference lineages: East African (ECSA), West African, Asian, and the Indian Ocean Lineage (IOL).
• Clinical Analysis:
  • Clinical data from 31 confirmed CHIKV cases were compared against 741 non-CHIKV AFI cases.
  • Statistical associations (Chi-square or Fisher's exact test) were calculated for symptoms to identify predictors of CHIKV infection.

3. Key Contributions

• First Molecular Characterization (2017–2020): Provided the first comprehensive genomic data on CHIKV strains circulating in Kenya during this specific period, filling a critical surveillance gap.
• Clinical Differentiation: Identified specific clinical symptoms that statistically differentiate CHIKV from other AFIs in a Kenyan pediatric and adult population.
• Mutation Tracking: Mapped the accumulation of specific amino acid substitutions known to enhance viral fitness and transmissibility in mosquito vectors.
• Geographic Structuring: Demonstrated distinct phylogenetic clustering between coastal (Mombasa) and northern (Dadaab) outbreaks, suggesting sustained local transmission rather than a single continuous spread.

4. Key Results

A. Molecular and Phylogenetic Findings:

• Lineage: All sequenced strains belonged to the Indian Ocean Lineage (IOL) of the East-Central-South African (ECSA) genotype.
• Geographic Clustering:
  • Mombasa: Strains formed a tightly clustered clade with short branch lengths, indicating sustained local transmission during 2017–2018.
  • Dadaab-Hagadera: Strains formed a distinct, separate clade from Mombasa, indicating independent local transmission cycles.
• Key Mutations:
  • Vector Fitness: All samples possessed E1-K211E and E2-V264A, mutations associated with increased transmission efficiency in Aedes aegypti.
  • IOL Marker: E1-A226V was present in 100% of samples, confirming the IOL lineage.
  • Mombasa Specifics: High prevalence of E1-T82I (81.3%) and E1-V84D (62.5%), located in the fusion loop, suggesting secondary adaptive steps.
  • Shared Mutations: Both locations shared nsP1-A104V and E2-I94V, suggesting circulation of closely related lineages or convergent evolution.
  • Viral Passage Artifacts: The passaged isolate (S32) showed non-synonymous substitutions in nsP1 and E2, likely induced by cell culture adaptation.

B. Clinical Characteristics:

• Positive Predictors: The following symptoms were significantly more common in CHIKV cases compared to other AFIs:
  • Sore muscles (10% vs. 0%, p < 0.001)
  • Headache (6% vs. 0%, p = 0.0016)
  • Convulsions (61% vs. 18%, p < 0.001)
• Negative Predictor:
  • Diarrhea was significantly less frequent in CHIKV cases (3% vs. 32%, p = 0.0013), suggesting its presence may help rule out CHIKV.
• Non-Significant Symptoms: Cough, skin rash, conjunctivitis, and vomiting showed no significant association with CHIKV.
• Limitation: Joint pain (a hallmark symptom) was not collected in the dataset, and the high rate of convulsions may be influenced by the young median age of the study cohort.

5. Significance and Implications

• Public Health Surveillance: The study confirms that the IOL genotype is the driver of recurrent outbreaks in Kenya. The presence of fitness-enhancing mutations (E1-K211E, E2-V264A) indicates a high risk of extensive outbreaks and potential spread to new ecological niches.
• Diagnostic Strategy: In resource-limited settings lacking point-of-care diagnostics, clinicians can use the presence of sore muscles, headache, and convulsions (and the absence of diarrhea) to prioritize CHIKV testing and differential diagnosis.
• Vaccine and Therapeutic Targets: The identification of conserved mutations in envelope proteins (E1, E2) and non-structural proteins (nsP1, nsP3) provides critical data for designing vaccines and antivirals that target the currently circulating strains.
• Future Outlook: The study highlights the need for continuous molecular surveillance to monitor the accumulation of mutations that could alter transmission dynamics or virulence, as evidenced by subsequent outbreaks reported in 2022.